BLOPEPBOLANG BIOTECHNOLOGY

Erythropoietin-derived peptide

ARA-290

ARA-290 is an erythropoietin-derived peptide investigated in tissue-protection and neuropathy research, including a phase 2 study in type 2 diabetes.

BLOPEP vial — representative image
Representative image
Quantity per vial

Select variantCompare prices and choose a variant to set the quantity and add it to your quote.

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings →

Mechanism and findings

Human study · Study formulation · People with type 2 diabetes and painful neuropathy

Exploratory metabolic and neuropathy outcomes

A phase 2 placebo comparison reported changes in metabolic and neuropathy endpoints and called for further evaluation.

Brines et al., 2015 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

ARA-290 — erythropoietin-derived peptide. The literature identity must be matched to the documented chemical form and composition of the supplied material.

ARA-290 was designed from erythropoietin to investigate innate repair receptor signaling without reproducing its hematopoietic activity. The cited clinical evaluation followed metabolic markers, neuropathic symptoms and corneal nerve fibers in type 2 diabetes.

  • Innate repair receptor

Brines et al., 2015

Studied findings 1
Human study · Study formulation

Exploratory metabolic and neuropathy outcomes

People with type 2 diabetes and painful neuropathy

A phase 2 placebo comparison reported changes in metabolic and neuropathy endpoints and called for further evaluation.

View context
Study design
Original-study abstract; experimental design described in linked source
Sample scope / arm
Not extracted; consult original study
Comparator
See original-study context
Experimental context (not instructions for use)
Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract
Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

Brines et al., 2015

Sources and studies 2
  1. ARA-290 — PubChem molecular identity

  2. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

    Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A · 2015 · Molecular medicine (Cambridge, Mass.)

    DOI: 10.2119/molmed.2014.00215

Specifications and packaging

Nominal variant content; analytical results belong to the documented batch.

Material type
Peptide
Molecular formula (literature identity)
C51H84N16O21
Molecular weight (literature identity)
1257.3 g/mol

Quality and analyses

Review specifications, analytical results and documentation for published batches.

Purity
>99%
Type
Declared specification

Published batches

Batch results have not yet been published on this page.

Look up batch

Storage

Consult the specific conditions in the supplied material documentation.

Delivery and commercial terms

Freight, timing and import terms will be confirmed in the quote for the selected destination.

Other materials in this area

View category →